ARTL — Q2 2026 Financial Report Analysis

Overview

Artelo Biosciences is a clinical-stage drug developer with no products on the market, so its quarterly results come down to three questions: how much cash it is spending, what it is spending it on, and how long the money lasts. In the second quarter of 2026 (three months to June 30) its net loss narrowed to $2.43 million from $3.22 million a year earlier. That was not because anything was earned. Research spending fell by more than half, to $0.88 million from $1.87 million. The company says the drop is "related primarily to [the] CAReS trial", its mid-stage study of lead drug ART27.13 in cancer-related appetite loss. Meanwhile overhead (general and administrative costs) rose 27% to $1.63 million. In the quarter, Artelo spent almost twice as much running the company and raising money as it did on research.

The balance sheet looks better than it did in December only because of a March fundraise. That raise also multiplied the share count about sevenfold. The company still warns there is "substantial doubt" about its ability to keep operating for the next year.

At a glance

• R&D spend of $0.88M, down 53% from a year earlier. CAReS professional fees (mostly payments to outside trial contractors) fell to $0.21M from $2.19M. The lead trial is costing much less to run, but the filing gives no new enrolment figure for 2026.
• Cash of $4.2M at June 30, up from $0.6M in December, after an ~$11.0M private placement in March. First-half operating cash burn was $6.2M, so this is a cushion of a few quarters, not years.
• 4.6 million shares outstanding on August 11, against 0.67 million on December 31. Existing holders' stakes have been diluted roughly 6.8 times in seven months, and 7.06 million warrants on top could add more.

The numbers

Artelo reports no revenue ("To date, we have not generated any revenue"). The comparison below is about costs. Figures are in USD; loss per share reflects the 1-for-3 reverse split of March 2026 (a reverse split merges existing shares into fewer, higher-priced ones).

n/m = not meaningful. The fall in loss per share from -$16.86 to -$0.89 reflects many more shares, not a smaller loss. The share base grew about 14-fold while the loss shrank by a quarter.

For the first half (six months to June 30), the operating loss was $5.19M against $5.53M. R&D was $1.65M against $3.26M, and G&A was $3.55M against $2.27M. Net loss was $5.39M against $5.59M.

Pipeline: where the science stands

Artelo has three programmes, all based on the body's cannabinoid signalling system:

• ART27.13 (lead): a drug licensed from work originally done at AstraZeneca, being tested for cancer anorexia, the appetite and weight loss that the filing says affects about 60% of advanced-stage cancer patients. It is in the Phase 2a part of the CAReS trial. Phase 2a is an early test of whether the drug works in patients, after Phase 1 safety testing. The target is 40 evaluable patients, randomised 3:1 to drug or placebo. The last enrolment figure in the filing is still "As of December 31, 2025, 32 participants have been enrolled". The latest efficacy data are the September 2025 interim readout. Patients titrated to the top dose (n=5) gained 6.38% of body weight over 12 weeks, versus a 5.42% loss on placebo (n=6). The groups are very small, and the standard deviations (9.50 and 8.17 points) are larger than the effects themselves. That is why the full Phase 2a readout matters.
• ART26.12: a pill-form inhibitor of a protein called FABP5, aimed first at nerve pain caused by chemotherapy (CIPN). It finished a Phase 1 single-dose safety study in healthy volunteers in 2025 with no drug-related adverse events in the blinded data. The filing describes no next-stage trial as started.
• ART12.11: a patented crystal form of CBD paired with another compound (TMP), still at the pre-clinical stage (animal studies).

The Q2 filing reports no new clinical data and no new trial starts. Its pipeline section largely repeats 2025 milestones.

What the headline numbers hide

• The loss narrowed because research slowed, not because the business improved. Professional fees inside R&D, which the company ties mainly to CAReS, fell by $1.99M year over year. That more than explains the whole $0.79M improvement in net loss. G&A rose by $0.35M in the quarter and by $1.27M (+56%) in the half. The company attributes this to "increased professional fees… related to our financing activities and increases in the service cost of stock-based compensation". Stock-based compensation, meaning pay in shares or options rather than cash, was $0.97M in the half against $0.34M a year earlier.
• The 2025 comparison is flattered by a tax credit. First-half 2025 R&D was reduced by a $0.70M UK government R&D tax credit, and no credit was received in 2026. Like for like, the cut in research spending is larger than the reported -49% for the half.
• Cash burn ran ahead of the reported loss. Operating cash outflow in the first half was $6.22M, against a $5.39M net loss. The gap mostly comes from paying down about $1.97M of overdue bills to suppliers and related parties, which the company says it had "postponed due to … cash preservation efforts" in 2025. Excluding that catch-up, the underlying burn was roughly $4.3M per half, or about $2.1M a quarter (our calculation from the cash-flow statement).
• Going-concern warning. The company states its circumstances "raise substantial doubt about the Company's ability to continue as a going concern within one year". A going-concern warning means management cannot show it has enough money to keep operating for the next 12 months without raising more.
• Heavy dilution, and more is possible. The March private placement sold shares and pre-funded warrants at $3.45 (pre-funded warrants are near-free options that work like shares), plus two warrants per unit exercisable at $3.20. Gross proceeds were about $11.0M, or $10.0M net. By June 30, 7.06M warrants were outstanding at a weighted average exercise price of $4.13. That is more than the 4.6M shares outstanding. The filing gives their intrinsic value (what they are worth if exercised today) as $0, meaning the share price was below their exercise prices. Post-quarter sales under the new at-the-market programme (selling new shares gradually into the market) raised $354K net for 386,668 shares. That implies roughly $0.92 a share, against the $3.45 March price. Shareholders also approved raising authorised shares to 500M from 166.7M on July 17.
• One-offs in the quarter were small. A $42K gain from paying off all convertible notes early (debt that can convert into shares), plus $42K of interest income. For the half, a $146K derivative loss on those notes also appears. All convertible debt is now gone, which removed a source of discounted, variable-price share issuance.
• Why the amendment was filed. We read the amended 10-Q/A filed on August 20, 2026. It changes nothing in the financial statements. Its sole purpose is to add a legal-proceedings disclosure "inadvertently omitted" from the original: a FINRA arbitration claim by Craft Capital Management. Craft says Artelo breached a right-of-first-refusal clause when it cancelled their engagement days before the March placement. It seeks an $880,000 success fee and warrants valued at $880,000, plus fees and interest. Artelo has filed counterclaims and says it does not expect a material impact. Still, a ~$1.76M claim is equal to about 40% of June 30 cash.
• A small inconsistency. The MD&A's six-month table shows a net loss of $5,355K. The income statement and cash-flow statement show $5,385K, and $5,355K is the total comprehensive loss. We use the income-statement figure.

Takeaway: Artelo's smaller loss this quarter is a sign of a company conserving cash, not of progress. Research spending halved while overhead and financing costs rose, and the $4.2M in the bank covers roughly two quarters at the current underlying burn. More dilutive fundraising is very likely before the CAReS Phase 2a readout that will decide the lead drug's prospects.

Outlook

Management gives no financial guidance or readout date. It says only that R&D spending will be "directly dependent upon the level of our available funding" and that G&A should stay "broadly comparable to the level… incurred year-to-date". At about $2.1M a quarter of underlying cash burn, $4.2M of June cash (plus $0.35M from post-quarter share sales) lasts into roughly the end of 2026 (our estimate; the company does not give one). Tools are in place to raise more: the $6.53M at-the-market programme, a $25M equity line with an investment fund, and a $75M shelf registration (pre-approval to sell securities). But at a share price that appears to be under $1, each dollar raised costs existing holders far more shares than in March.

What to watch next quarter:

1. CAReS enrolment and timing: whether the trial reaches its 40-patient target, and whether a date is given for full Phase 2a data. That is the one event that could change the company's financing terms.
2. Cash at September 30 and new share issuance: whether the at-the-market programme or equity line is drawn heavily, and how far the share count rises beyond 4.6M.
3. Share price and listing: the implied ~$0.92 issue price is below Nasdaq's $1 minimum bid requirement. Another reverse split (there have already been two since June 2025) would be a sign of continued pressure.
4. The Craft arbitration: any settlement or award, given its size relative to cash.

Source: Artelo Biosciences Form 10-Q for the quarter ended June 30, 2026 (filed August 12, 2026), read together with Form 10-Q/A Amendment No. 1 (filed August 20, 2026, link), which added only the legal-proceedings disclosure above.